Skip to Content

Vizimpro Side Effects

Generic Name: dacomitinib

Note: This document contains side effect information about dacomitinib. Some of the dosage forms listed on this page may not apply to the brand name Vizimpro.

For the Consumer

Applies to dacomitinib: oral tablet

Along with its needed effects, dacomitinib (the active ingredient contained in Vizimpro) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking dacomitinib:

More Common

  • Blistering, crusting, irritation, itching, or reddening of the skin
  • body aches or pain
  • chest pain
  • chills
  • cough
  • cracked lips
  • cracked, dry, or scaly skin
  • deep cracks, grooves, or lines in the skin
  • diarrhea
  • difficulty in swallowing
  • ear congestion
  • fever
  • headache
  • itching, skin rash
  • loosening of the fingernails
  • loss of voice
  • nasal congestion
  • redness or soreness around the fingernails
  • redness, swelling, or pain of the skin
  • runny nose
  • scaling of the skin on the hands and feet
  • sneezing
  • sore throat sores, ulcers, or white spots on the lips, tongue, or inside the mouth
  • swelling
  • tightness in the chest
  • tingling of the hands and feet
  • trouble breathing
  • ulceration of the skin
  • unusual tiredness or weakness

Less Common

  • Confusion
  • decreased urination
  • dizziness
  • dry mouth
  • fainting
  • fever
  • increase in heart rate
  • lightheadedness
  • loss of heat from the body
  • rapid breathing
  • sunken eyes
  • thirst
  • wrinkled skin

Some side effects of dacomitinib may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More Common

  • Burning, dry, or itching eyes
  • change in taste
  • constipation
  • decreased appetite
  • decreased weight
  • discharge, excessive tearing
  • hair loss or thinning of hair
  • increased hair growth on the forehead, back, arms, and legs
  • lack or loss of strength
  • loss of taste
  • nausea
  • redness, pain, or swelling of the eye, eyelid, or inner lining of the eyelid
  • trouble sleeping
  • vomiting

Less Common

For Healthcare Professionals

Applies to dacomitinib: oral tablet

Hematologic

Very common (10% or more): Anemia (44%), hypoalbuminemia (44%), lymphopenia (42%)[Ref]

Musculoskeletal

Very common (10% or more): Pain in extremity (14%), musculoskeletal pain (12%)[Ref]

Ocular

Very common (10% or more): Conjunctivitis (19%)

Common (1% to 10%): Keratitis[Ref]

Metabolic

Very common (10% or more): Hyperglycemia (36%), hypocalcemia (33%), decreased appetite (31%), decreased weight (26%), hyponatremia (26%), alkaline phosphatase increased (22%), hypomagnesemia (22%)

Common (1% to 10%): Dehydration[Ref]

Psychiatric

Very common (10% or more): Insomnia (11%)[Ref]

Hepatic

Very common (10% or more): ALT increased (40%), AST increased (35%), hyperbilirubinemia (16%)[Ref]

Respiratory

Very common (10% or more): Cough (21%), nasal mucosal disorder (i.e., epistaxis, nasal inflammation, nasal mucosal ulcer, rhinitis) (19%), dyspnea (13%), upper respiratory tract infection (12%), chest pain (10%)[Ref]

Other

Very common (10% or more): Asthenia (13%)

Common (1% to 10%): Fatigue[Ref]

General

The most common (greater than 20%) adverse reactions were diarrhea (87%), rash (69%), paronychia (64%), stomatitis (45%), decreased appetite (31%), dry skin (30%), decreased weight (26%), alopecia (23%), cough (21%), and pruritus (21%).[Ref]

Nervous system

Common (1% to 10%): Dysgeusia[Ref]

Renal

Very common (10% or more): Creatinine increased (24%)[Ref]

Dermatologic

Very common (10% or more): Rash (i.e., dermatitis acneiform, rash, rash maculopapular)/exfoliative skin reactions (78%), paronychia (i.e., nail infection, nail toxicity, onychoclasis, onycholysis, onychomadesis) (64%), dry skin (i.e., xerosis) (30%), alopecia (30%), pruritus (21%), palmar-plantar erythrodysesthesia syndrome (15%), dermatitis (11%)[Ref]

Gastrointestinal

Very common (10% or more): Diarrhea (87%), stomatitis (i.e., mucosal inflammation) (45%), nausea (19%) constipation (13%), mouth ulceration (12%)

Common (1% to 10%): Vomiting[Ref]

References

1. "Product Information. Vizimpro (dacomitinib)." Pfizer U.S. Pharmaceuticals Group, New York, NY.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.

Related questions

Hide